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ABSTRACT: A flow-through microvial is used to interface capillary electrophoresis and mass spectrometry (CE-MS) to develop
a method for simultaneous profiling both neutral and sialylated glycans without derivatization or labeling. The CE separation was
performed at near-zero electroosmotic flow in a capillary with neutral, hydrophilic coating, using 50 mM ammonium acetate in
20% methanol (pH 3.1) as the background electrolyte. The method was optimized with reversed CE polarity and negative ion
ESI-MS. Enzymatically released N-glycans from human immunoglobulin G (IgG) were used as the test sample. The approach
was also used to study the more complex N-glycans from recombinant human erythropoietin (rHuEPO) expressed in Chinese
hamster ovary (CHO) cells. Glycoscreening of rHuEPO was performed using a triple quadrupole MS and an ultrahigh resolution
TOF-MS. The high sensitivity and high mass accuracy of the TOF-MS revealed the presence of more than 70 glycans. Three
mono- and di-sialylated tetra-antennary N-glycans and one mono-sialylated tri-antennary N-glycan of rHuEPO are reported for
the first time. Further glycan heterogeneity was identified of the highly sialylated N-glycans of rHuEPO by extensive acetylation,
Neu5Ac/Neu5Gc variation and the presence of N-acetyl-lactosamine repeats. For comparative purposes, porous graphitic
carbon-based LC-MS/MS was also used to glycoprofile rHuEPO. This work demonstrates the potential of CE-MS to provide a
comprehensive glycosylation profile with detailed features of the secondary glycan modifications. The CE-MS based method
eliminates the need to label the N-glycans, as well as the requirement to desialylate before analysis, and could complement other
established techniques for glycan characterization of therapeutic glycoproteins.
Characterizing glycosylation of proteins is still one of themost challenging tasks for bioanalytical chemists. The
non-template control of the biosynthetic pathway of glyco-
sylation is the basis for the great complexity of glycans.1
Extensive microheterogeneity often occurs at the glycosylation
site of proteins, leading to a large glycoform population.
Because protein glycosylation plays a key role in a wide range of
biological processes, aberrant protein glycosylation in mamma-
lian systems is often associated with pathogenesis.2
Given the potential of recombinant glycoproteins as
therapeutic drugs and diagnostic reagents, the analysis of
protein glycosylation has attracted much interest in recent
years.3−5 Glycotyping, a comprehensive and detailed character-
ization of the various glycoforms present in a glycoprotein, has
been used to detect subtle yet biologically relevant differences
in glycan composition of different batches of glycoprotein
pharmaceuticals.6,7 Such differences can affect their biological
activities and influence drug safety, efficacy, and stability.8 The
common practice to determine the glycan composition of
recombinant or plasma-purified protein therapeutics involves
the enzymatic release of the carbohydrate moiety with
endoglycosidases (peptide N-glycosidase F or A), followed by
the analysis and detection of either labeled or underivatized
glycans.3,9,10
Various chromatographic methods have been used for the
analysis of enzymatically released glycans. Hydrophilic-inter-
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action chromatography (HILIC),4,11 porous graphitized carbon
(PGC) LC-MS,5,12 and reversed-phase liquid chromatography
(RP-LC),13,14 are routinely used for identifying glycan
components in complex mixtures. However, since glycans are
typically hydrophilic, they are not well retained by RP-LC, and
common alternatives, such as HILIC and PGC, that better
retain hydrophilic glycans, often result in longer retention times
versus RP-LC. Additionally, these processes often require time-
consuming derivatization processes with fluorophores that can
introduce bias in the detection sensitivity of the glycans because
of the purity of the labeling reagents or the derivatization
steps.15,16 Over the past few years, online coupling of capillary
electrophoresis (CE) to time-of-f light mass spectrometry (TOF-
MS) detection has emerged as an attractive and complementary
technique for characterization of biomolecules.17−20 Because
CE-TOF-MS combines high separation efficiencies with high
mass resolution and mass accuracy, it may be a powerful
method for glycan analysis. CE-MS of carbohydrates has been
previously done with coaxial sheath-liquid21,22 and sheathless
interfaces.23 Although sheath-liquid CE-MS interfaces are
relatively stable and robust, the required high volumetric flow
of sheath-liquid contributes to considerable analyte dilution in
comparison to sheathless CE-MS interfaces. The use of
sheathless CE-MS interfaces often face difficulties in fabrication
and operation. Unlabeled carbohydrate analysis using sheathless
interfaces have been reported to be extremely slow (∼120 min)
for routine use when CE in reverse polarity was performed.23
We have previously described a novel flow-through microvial
interface in which a chemical modifier solution mixes with the
CE effluent and delivers the analyte from the capillary terminus
to the source.24 The major advantages of this interface are that
(i) the modifier solution is delivered at low flow rates, typically
100−500 nL/min to minimize analyte dilution, and (ii) the
stainless steel electrospray emitter holds the separation capillary
inside, making the operation very robust. The beveled shape of
the electrospray emitter stabilizes the ESI spray in a wide range
of flow rates.25 Successful applications of this low flow sheath-
liquid interface have been reported for the analysis of
fluorescently labeled carbohydrates,26 separation of isomeric
O-acetylated N-glycans in fish serum,27 monitoring prostate
cancer biomarkers,28 sensitive metabolic profiling studies,29 and
for the coupling of capillary isoelectric focusing (cIEF) to MS.30
In this article, we describe a relatively simple approach
including enzymatic digestion, SPE purification, CE separation,
and MS detection of underivatized neutral and acidic N-glycans
from immunoglobulin G (IgG) and recombinant human
erythropoietin (rHuEPO). Unlabeled glycans were analyzed
to preserve their native structural characteristics and to avoid
time-consuming derivatization procedures. Glycosylation of
rHuEPO was also studied using online liquid chromatography−
mass spectrometry (LC-MS) to evaluate its ability, in
comparison with CE-MS, to detect underivatized glycans
along with their secondary modifications.
■ EXPERIMENTAL SECTION
Materials. See Supporting Information.
Glycoprotein Deglycosylation with PNGase F. N-
glycans from purified rHuEPO (see Supporting Information)
and IgG from human serum were released by enzymatic
digestion with PNGase F. rHuEPO (50 μg) or 100 μg of
human IgG were adjusted to a final volume of 50 μL with 10
mM Tris-HCl at pH 8.0. Samples denaturation was achieved by
adding 2.5 μL of denaturation solution, containing 0.1% sodium
dodecyl sulfate and 50 mM β-mercaptoethanol, and heating at
100 °C for 5 min. Samples were then treated with 2.5 μL of
detergent solution containing 0.75% NP-40, followed by 2 μL
of PNGase F (1000 mU). The solutions were incubated
overnight at 37 °C.
Electrophoretic Procedure. CE-MS analyses of SPE-
purified N-glycans (see Supporting Information) were
performed using hydrophilic hydroxypropyl cellulose-coated
capillaries (HPC-capillaries) prepared in-house according to the
method of Shen and Smith.31 Capillaries were of 70 cm length
and 50 μm id. Separations were carried out in reverse-polarity
mode at −25 kV with an overimposed pressure of 10 mbar
(0.145 psi) to reduce analysis time for neutral glycans.
Background electrolytes (BGE) were composed of 30−100
mM ammonium acetate (pH 3.0−4.0) with 20% methanol. The
samples were injected at 1.0 psi for 10 s, corresponding to a
volume of 19 nL.
CE-ESI-MS System. CE-ESI-MS analyses of N-glycans were
carried out with a PA800 plus capillary electrophoresis system
(Beckman Coulter, Brea, CA) coupled to an API 4000 triple-
quadrupole mass spectrometer (AB SCIEX, Concord, Canada).
A modified capillary cartridge that permits external detection
was used for the analysis. The CE-MS interface with a flow-
through microvial was developed in our laboratory and has
been described previously.24,26−30,32 The electrospray voltage
was set at −3.5 kV. Data acquisition and system control were
performed using the Analyst 1.4.2. software (AB SCIEX,
Framingham, MA, U.S.A.). The modifier solution was delivered
by a syringe pump (Harvard Apparatus, Holliston, MA, U.S.A.)
at a flow rate of 0.3 μL/min and was composed of 10 mM
ammonium acetate (pH 3.1) containing 75% of 2-propanol and
methanol (2:1 ratio). The same interface setup and solutions
were used for CE-ESI-MS with an HP 3DCE (Agilent
Technologies, Waldbronn, Germany) coupled to a maXis
ultrahigh resolution TOF mass spectrometer (Bruker Daltonik,
Bremen, Germany). The mass spectrometer was operated in
negative ionization mode and acquired data in full scan mode
with a mass range from m/z 500−3000 at a spectra rate of 1
Hz. Optimization of the transfer parameters and MS calibration
were performed with TuneMix (Agilent Technologies) in order
to obtain the best sensitivity at satisfactory resolution (R ≈ 20
000 at m/z 1334). Instrument control and data analysis were
performed using ESI Compass 1.3 application software from
Bruker (Bruker Daltonik, Bremen, Germany). The conditions
for modifier solution and its delivery rate are the same as the
ones when the API 4000 MS was used.
■ RESULTS AND DISCUSSION
Analysis of N-Glycans from Human IgG. Complex bi-
antennary, core-fucosylated and partially galactosylated, and
sialylated oligosaccharides are typically found at the single N-
glycosylation site of human IgG, located in the constant region
of the heavy chain.33 The variable presence of bisecting GlcNAc
and α-2,3- or α-2,6-linked sialic acids on terminal galactose
residues contribute to the glycan heterogeneity.34 Despite
human IgGs are characterized by relatively simple glycosylation
profiles, changes in their glycosylation are associated with
immune responses and with the activity of recombinantly
expressed monoclonal antibodies (mAbs) for therapeutic
purposes.34,35
Regarding the clinical role of mAbs, it is crucial an in-depth
characterization of their glycosylation for activity, safety and
quality control during development and production.36 Because
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of the utmost importance of glycosylation in human IgG for its
biological and clinical functions, here we present a simple and
efficient method for analyzing its N-glycosylation profile by CE-
MS. The method will be further used to explore the N-
glycosylation of rHuEPO.
Based on our experience in analyzing underivatized N-
glycans from fish serum,27 we used neutral coated capillaries
and acidic background electrolytes (BGEs) to optimize the CE-
MS conditions for underivatized N-glycans from human IgG
(Supporting Information). Baseline separation between neutral
and sialylated N-glycans was achieved (Figure 1) and glycans
were detected as [M − H]− and [M − 2H]2− ion species.
Sialylated glycans migrated faster than neutral glycans because
of their electrophoretic mobility enhanced by the acidic BGE in
reversed polarity mode.23 Among sialylated species, separation
occurred based on the number of sialic acid residues and the
hydrodynamic volume of the glycans. The overimposed
pressure of 10 mbar (0.145 psi) and the interaction of neutral
glycans with acetate ions allowed the glycans to migrate toward
the anode. Although baseline separation in the time dimension
was not achieved for all the glycan species, the orthogonal
baseline MS resolution allows direct analysis of underivatized
neutral and acidic glycans in a single run, providing a detailed
glycoprofile of the complex glycoprotein. The presented
methodology also eliminates the need to label the glycans, as
well as the need to remove sialic acid residues prior to their
analysis as it has been commonly reported for acidic glycans of
different sources.37,38
As outlined in Table S.I. (Supporting Information), 22
glycans of IgG were identified. Putative glycan monosaccharide
compositions were assigned based on accurate precursor mass
data and previous reports on N-glycosylation analysis of human
IgG.39−41 The number of glycans observed in IgG contrasts
with the large heterogeneity found in other glycoproteins of the
immune system.42 For instance, a single GPI-anchored
glycoprotein, CD59, has been reported to contain over 120
glycoforms.42
CE-MS Analysis of N-Glycans from rHuEPO. Previous
CE-MS studies on N-glycosylation of rHuEPO were performed
using bare-fused silica capillaries in basic background electrolyte
(BGE) conditions.10,43 To enhance mobility differences of
glycoforms and to avoid compromising spray stability or signal
intensity that may occur in basic BGE, our CE-MS method
employs neutral hydrophilic (HPC)-coated capillaries under
acidic BGE conditions. N-glycan population from rHuEPO is
mainly composed of core-fucosylated tetra-antennary glycans
containing variable numbers of sialic acids. Tri-antennary N-
glycans containing up to 3 sialic acid residues and di-antennary
N-glycans containing up to 2 sialic acid residues are also present
but with lower abundance than tetra-antennary structures.6,8,44
Because N-glycans from rHuEPO are highly sialylated, they
remain negatively charged over a broad pH range and can be
easily CE separated and detected in negative ion ESI-MS
without derivatization or glycan labeling. Analyzing under-
ivatized glycans is desirable not only to simplify the sample
preparation but also to preserve their native structural
characteristics. The most common derivatization strategy for
CE analysis of N-glycans is reductive amination,45 in which the
combination of acidic conditions and high temperatures present
a considerable risk for loss of sialic acids, which could
contribute to an increased heterogeneity.46 Removal of the
excess of labeling reagent can also be problematic and labor-
intensive because of the similar properties of the labeling and
the derivatized glycans. Therefore, the analysis of underivatized
glycans is preferred to reduce the risk of bias because of sample
handling and the potential loss of sialic acids.
Figure 2 shows the base peak electropherogram (BPE) of the
17 most abundant N-glycans from rHuEPO detected with a
triple quadrupole MS. Separation of N-glycans is achieved
based on different electrophoretic mobilities influenced by the
number of sialic acids residues, N-acetyl-lactosamine (LacNAc)
repeat units, and the hydrodynamic volume of the glycans.
Glycans with an increased number of sialic acids display a
stronger mobility toward the anode and appear earlier in the
electropherogram. As expected, heavier glycans containing the
Figure 1. Density map for the CE-ESI-MS separation of neutral and
acidic N-glycans from human IgG. Conditions: Neutral (HPC)-coated
capillary 70 cm × 50 μm; BGE, 50 mM ammonium acetate/20%
methanol (pH 3.1); separation voltage, −25 kV + 10 mbar; negative
ion ESI-MS; modifier solution, 10 mM ammonium acetate (pH 3.1)
containing 75% of 2-propanol: methanol (2:1). The intensity of the
color reflects the glycan abundance with light green being less
abundant that dark blue.
Figure 2. EIE for the CE-ESI-MS separation of N-glycans from
rHuEPO. Only the 17 most abundant N-glycans are displayed. The
glycans were detected under the same CE-MS conditions as in Figure
1. The monosaccharide composition of the glycans is indicated in the
graph. Nomenclature is as follows: H = mannose or galactose (Hex),
N = N-acetylglucosamine (HexNAc), F = fucose, and S = sialic acid
(Neu5Ac). Data was acquired using the triple quadrupole MS.
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same number of negative charges have a reduced mobility and
are detected later in the electropherogram. Smaller species
containing variable amounts of sialic acids migrate faster than
larger species according to the LacNAc extension of the chain.
Although the detected glycans are not fully time-resolved,
sialylated glycans displaying the same charge but containing
variable number of hexoses (Hex) and/or LacNAc units
(161.05 or 364.1 Da, respectively) can be profiled and
distinguished in the MS, showing the excellent separation
power of the technique to resolve structurally similar N-glycans.
Some abundant glycans, such as tetra-antennary glycans with
3−4 sialic acid residues are detected as broad peaks because of
the co-migration of their acetylated and/or Neu5Ac/Neu5Gc
variations and because of the diffusion process that can occur
under negligible EOF conditions. Band broadening properties
in CE-MS have been recently discussed in a publication from
our research group.32
Putative monosaccharide compositions, observed masses and
m/z values for glycans shown in Figure 2 are summarized in
Table 1. The precursor mass data obtained from the triple
quadrupole MS were used to search for matching compounds
in the Consortium of Functional Glycomics (CFG) for N-
linked glycans. In agreement with other reports, all released
glycans of rHuEPO contain a fucosylated core with variable
degrees of sialylation.47−49 Using the developed method, we
detected the same population of glycans from rHuEPO
expressed by CHO cells previously reported.10,47,49−51 We
also identified additional species that were not reported before:
two tetra-antennary glycans (mono- and di-sialylated) and one
mono-sialylated tri-antennary glycan, with the monosaccharide
compositions H8N7F1S1, H9N8F1S2, and H6N5F1S1,
respectively. Glycans with acetylation and/or Neu5Ac/
Neu5Gc variations with putative compositions H8N7F1S1
and H9N8F1S2 were also observed (Table S.II, Supporting
Information). Assignment of glycan monosaccharide composi-
tion could be based on the observed precursor mass alone
because of the restricted combinations of monosaccharide
residues of N-glycans.52 For each glycan monosaccharide
composition there are several possible isomeric structures and
different types of glycosidic linkages that cannot be identified
by single stage CE-MS analysis. Differences in electrophoretic
mobilities, resulting in differential migration time for glycans,
can be useful to predict the structure of certain glycans. For
instance, the monosaccharide composition of glycan
H8N7F1S3 (Table 1) matches both with the structure of a
tri-antennary glycan with two LacNAc units and with the
structure of a tetra-antennary glycan with one LacNAc unit.
The longer migration time of glycan H8N7F1S3 in comparison
to that of glycan H7N6F1S3, a tetra-antennary species,10
suggests that glycan H8N7F1S3 may be a tetra-antennary
species with one LacNAc repeat. The increased volume of
glycan H8N7F1S3 in comparison to glycan H7N6F1S3,
reduces its electrophoretic mobility and appears later in the
electropherogram.
To accurately determine the mass of the glycans, our flow-
through microvial interface was connected to a maXis ultra
high-resolution TOF MS, which offers a wider mass range,
higher resolution and higher mass accuracy than the triple
quadrupole MS. In addition to the glycans detected before, a
mono-sialylated tetra-antennary glycan with three LacNAc units
(monosaccharide composition H10N9F1S1) that has not been
previously reported by CE-MS was detected with the TOF MS.
In total, more than 70 N-glycans were observed of which
several could be identified, as shown in Supporting Information
Table S.II. A complete list of the glycans observed for BRP
rHuEPO is shown in Supporting Information Table S.II,
including monosaccharide composition, theoretical mass,
observed mass, and m/z values. Glycans were identified based
on their true isotopic pattern provided by the ESI Compass 1.3
application software from the maXis TOF MS in combination
with the information provided by the Consortium of Functional
Glycomics (CFG) for N-linked glycans. The high mass
accuracy, in the low ppm range (<1 ppm) and the resolving
power, of nearly 20 000 at m/z 1334 (Agilent ESI low
concentration tuning mix) of the TOF MS was also useful to
Table 1. Identification and Annotation of the 17 Most Abundant N-Glycan Monosaccharide Compositions of rHuEPO Shown
in Figure 2a
composition observed m/z
glycan H N F S theor. mass (Da) obsd mass (Da) [M − 2H]2− [M − 3H]3− [M − 4H]4−
H7N6F1S4 7 6 1 4 3683.33 3683.21 1226.7 919.7
H8N7F1S4 8 7 1 4 4048.67 4048.62 1348.5 1011.1
H9N8F1S4 9 8 1 4 4415.07 4415.10 1470.6 1102.7
H6N5F1S3 6 5 1 3 3026.74 3026.76 1512.3 1007.8
H10N9F1S3 10 9 1 3 4490.10 4489.95 1495.6
H7N6F1S3 7 6 1 3 3393.10 3392.97 1695.4 1129.9
H6N5F1S1 6 5 1 1 2444.22 2444.23 1221.0
H9N8F1S2 9 8 1 2 3833.51 3833.47 1276.8
H9N8F1S3 9 8 1 3 4124.80 4124.69 1373.8
H8N7F1S3 8 7 1 3 3758.20 3757.90 1251.6
H8N7F1S2 8 7 1 2 3467.49 3467.60 1154.8
H6N5F1S2 6 5 1 2 2736.50 2736.46 1367.1
H5N4F1S2 5 4 1 2 2371.17 2371.30 1184.6
H8N7F1S1 8 7 1 1 3171.85 3171.79 1056.2
H9N8F1S1 9 8 1 1 3539.24 3539.40 1768.6 1178.7
H10N9F1S4 10 9 1 4 4781.42 4781.37 1592.7
H7N6F1S2 7 6 1 2 3101.84 3101.77 1549.8 1032.8
aGlycans were observed as [M − 2H]2−, [M − 3H]3−, or [M − 4H]4− ion species. Data was obtained using the triple quadrupole MS. Nomenclature
of the glycan monosaccharide composition as indicated in Figure 2.
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confirm glycan modifications previously observed with the
triple quadrupole MS.
Detection of Glycan Modifications in rHuEPO. In
agreement with other reports, our CE-MS method revealed the
presence of three types of secondary glycan modifications in
enzymatically released N-glycans from rHuEPO.4,8,10,43,44
These modifications were mainly observed in highly sialylated
glycans and include acetylation of sialic acids, N-acetylneur-
aminic (Neu5Ac) / N-glycolylneuraminic acid (Neu5Gc)
variation, and elongation of the glycan chains because of the
presence of LacNAc repeats. Up to three modifications
occurred per glycan.
Acetylation of N-glycans was detected due to mass shifts of
42 Da from the naked glycan masses. The presence of a set of
peaks differing in 10.5 m/z (Th) for glycans observed as [M −
4H]4− ion species or 14 m/z (Th) for glycans observed as [M
− 3H]3− ion species, accounts for the acetylation of glycans.
For instance, the presence of a set of seven peaks additional to
the most abundant ion at m/z 919.53 for the tetra-sialylated
glycan H7N6F1S4, indicates the occurrence of 7 acetylated
forms that were resolved in the mass dimension (Figure 3A and
3B). Acetylated species were predominantly detected as [M −
4H]4− ion species, while [M − 3H]3− ions species were less
abundant. Higher acetylated forms of glycan H7N6F1S4 have a
reduced electrophoretic mobility compared to less acetylated
species and are detected later in the electropherogram. This is
illustrated in the extracted ion electropherogram (EIE) (Figure
3A), where the migration order of the glycans are in agreement
with the number of acetyl groups. Our CE-MS method
succeeded in detecting mobility differences due to only 42 Da,
corresponding to acetylation, in high molecular mass analytes
(2300−4800 Da, approximately) with an optimal MS
resolution. Acetylation of other glycans such as the tri-sialylated
H7N6F1S3 and the tetra-sialylated with one LacNAc repeat
H8N7F1S4, containing 4 and 6 acetylated forms, respectively,
were also observed and are discussed in the Supporting
Information. All acetylated N-glycans observed in rHuEPO are
included in Supporting Information Table S.II.
Figure 3. (A) EIE obtained for the CE-MS separation of the tetra-antennary tetra-sialic glycan H7N6F1S4 (peak 1) and its acetylated species
containing from 1 to 7 O-acetyl groups (peaks 1a to 1g, respectively). (B) Average MS spectrum obtained for panel A where it can be observed the
m/z values of the O-acetylated and Neu5Ac/Neu5Gc variations species of H7N6F1S4. The glycans were detected under the same CE-MS conditions
as in Figure 1
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CE-MS analysis of sialylated glycans shows that a higher
degree of acetylation is present in glycans containing a higher
degree of sialylation. This indicates that the acetylation occurs
at the sialic acid level due to the occurrence of Neu5,9Ac2, as it
has been reported before in rHuEPO.49 Based on the number
of sialic acid residues and O-acetyl groups observed, it can be
predicted that not only mono-O-acetylated sialic acid residues
are present but also multiple O-acetylated forms of sialic acids
occurs. For instance, the presence of 5, 6, and 7 O-acetyl
substituents in tetra- and tri-sialylated glycans implies multiple
O-acetylations occurring on a single sialic acid residue. This
phenomenon has also been reported during the glycoprofile of
rHuEPO,4,10,43 Dynepo,53 a novel recombinant human EPO,
darbepoetin,48 an hyperglycosylated glycoform and other
commercial EPOs produced in CHO cell lines.8 The degree
of acetylation of sialic acid deserves special attention because it
is correlated with the circulatory half-life of the glycoproteins in
the human serum and its in vivo biological activities.53,54 Also,
variability in the glycosylation pattern can potentially affect the
biological, physicochemical and immunological properties of
rHuEPO.55
rHuEPOs engineered in Chinese hamster ovary (CHO) cells
have a distinct set of glycans relative to recombinant EPOs
engineered in human fibrosarcoma cell lines and baby hamster
kidney (BHK) cells, because of the slightly different
glycosylation machineries including the sugar-transferring
enzymes.56,57 Contrary to human cells, CHO cells do not
express sialyl-α-2,6-transferase, α-1,3/4-fucosyltransferase and
bisecting N-acetylglucosamine transferase.47 However, these
cells contain the enzyme responsible for N-glycolylneuraminic
acid synthesis (CMP-N-acetylneuraminic acid hydroxylase
[CMAH]) that is not present in humans due to an internal
frame shift mutation in the CMAH human gene.58,59 For that
reason, rHuEPO expressed in CHO cells has been reported to
contain between 1 and 1.5% of Neu5Gc residues relative to the
total sialic acid content, while EPO products engineered by
gene-activation in human cells contain no Neu5Gc.8,57,60
Our CE-MS method detected the presence of Neu5Gc,
instead of Neu5Ac, in some N-glycans from rHuEPO. In some
cases, this sialic acid variation occurred simultaneously with the
acetylation of glycans previously discussed (Figure 3B). The
presence of a set of peaks differing in 4 m/z (Th) for glycans
observed as [M − 4H]4− ion species, correspond to mass shift
of 16 Da from the unmodified glycan masses, and accounts for
the Neu5Ac/Neu5Gc variation. For instance, the tetra-
sialylated glycan H7N6F1S4 and four of its acetylated forms,
containing one to four acetyl groups, displayed lower intense
peaks at 4 m/z (Th) higher than the corresponding acetylated
glycan. This type of modification was also observed in the tetra-
sialylated glycan H8N7F1S4 containing a LacNAc repeat, the
tri-sialylated glycan H7N6F1S3, and their corresponding
acetylated forms (Supporting Information). Other glycans
where the Neu5Ac/Neu5Gc variation occurred are shown in
Supporting Information Table S.II, along with their corre-
sponding putative monosaccharide composition. This phenom-
enon has not been extensively reported and there are only a few
studies in the literature dealing with the presence of Neu5Gc in
rHuEPO.8,10,44,53,60 Even though Neu5Gc is a common sialic
acid in most mammals, it has been demonstrated to be absent
in healthy humans and only small amounts have been found in
some tumors and meconium.61
The CE-MS method succeeded in detecting this hetero-
geneity of acidic monosaccharides without removing the sialic
acid from the glycan chain by acid hydrolysis as it has been
commonly reported.8,53,62 As reviewed lately, the LC-MS
detection of sialic acids and its heterogeneous subtypes is
challenging.63 Mass spectrometric results indicate that the
variation occurred at the glycan level as shown in Figure 3B and
Supporting Information (Figures S1.B and S1.D).
The third type of glycan modification corresponds to the
elongation of the glycan chain due to the presence of LacNAc
repeat units. For instance, tetra-antennary glycans, the most
abundant oligosaccharides present in rHuEPO, were observed
to contain up to three LacNAc extensions. Glycans with
monosaccharide compositions H8N7F1S4, H8N7F1S2;
H9N8F1S4, H9N8F1S3; H10N9F1S3 and H10N9F1S4 were
identified to carry one, two and three units of LacNAc,
respectively which are in agreement with other reports in the
literature.10,47,49,51 These extended oligosaccharides represent
the most important difference between circulating human EPO
and rHuEPO, and they have been reported as a critical
structural feature of rHuEPO that should be considered for its
biological significance.64 Recently, Bones et al.4 have reported
an increased number of LacNAc extensions containing up to
five units in BRP rHuEPO. In that study, successful detection of
tetra-antennary glycans with extensive LacNAc repeats was
based on a combination of weak anion exchange chromatog-
raphy (AEC) and HILIC that allowed for the first time the
detection of up to five LacNAc repeats.4
LC-MS/MS Analysis of N-Glycans from rHuEPO.
Underivatized, nonreduced N-glycans of rHuEPO were also
analyzed using online porous graphitized carbon (PGC) LC-
MS/MS to compare its ability to glycoprofile complicated
glycan mixtures with that of CE-MS. Table S.III in the
Supporting Information shows a list of the glycans detected
with PGC LC-MS/MS. A total of 27 glycan monosaccharide
compositions including a few acetylated species and three
neutral glycans were detected. Glycan heterogeneity such as
Neu5Ac/Neu5Gc variations and extensive acetylation of tri-
and tetra-sialylated glycans H7N6F1S3, H7N6F1S4, and
H8N7F1S4, observed with our CE-MS method, were not
detected with PGC LC-MS. The tetra-sialylated glycan
containing one LacNAc unit H8N7F1S4 was not detected by
PGC LC-MS either.
Successful LC-MS/MS analysis of glycans using PGC often
requires oligosaccharide reduction in the presence of mild
reducing agents or derivatization with hydrophobic compounds
prior to MS detection.5,65,66 However, those additional steps
can eliminate subtle modifications including O-acetylation
present in glycans (unpublished observation). Therefore, the
analysis of underivatized species is the preferred method of
choice to preserve the structural characteristics of these
complex analytes. Although both chromatographic and electro-
phoretic separation techniques are suitable for the profiling of
glycans, CE is advantageous because of its demonstrated
capability to analyze underivatized glycans and offers an
alternative and complementary analytical tool to chromato-
graphic based techniques. Our CE methodology has the
advantage of keeping the detailed structural information
about the glycans, which results in the detection of more
species, not only because of the type of MS employed, but also
because of the unique characteristics of the technique.
Moreover, CE-MS requires short analysis time for the study
of intact N-glycans, in comparison to LC-MS, which requires
longer times for separation and column re-equilibration. Taken
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together, this makes CE a well-suited analytical approach for
extensive glycan characterization.
■ CONCLUSIONS
In this study, we demonstrated the excellent potential of CE-
MS for glycan analysis using a flow-through microvial interface.
With our CE-MS method, we were able to characterize
heterogeneous mixtures of enzymatically released N-glycans
from human IgG and rHuEPO. Glycans released from IgG
were used to optimize the conditions for CE-MS analysis of
complex N-glycan mixtures. In total, 22 N-glycans, including
neutral and sialylated species of IgG were identified. The use of
hydrophilic HPC-coated capillaries that provide almost zero
EOF was necessary to allow successful separation of the N-
glycan mixtures. Underivatized glycans were used, because the
labeling procedure often affects the detection of glycan
modifications by inducing, for example, de-O-acetylation or
complete destruction of chemically unstable substituted sialic
acids. Also, it was not necessary to remove sialic acid residues.
Sialylated and neutral N-glycans from IgG were simultaneously
glycoprofiled to provide a general overview of the complex
glycan mixture, although it was not possible to achieve high
resolution for both neutral and sialylated species.
Application of the optimum CE-MS conditions for the
analysis of rHuEPO glycosylation, revealed the presence of
more than 70 N-glycans, including O-acetylation, Neu5Ac/
Neu5Gc heterogeneity and extension of the glycan chains due
to LacNAc repeats. The CE-MS method made it possible to
unravel the complexity of the carbohydrates and showed
detailed information about their minor glycan modifications.
This revealed the ability of the method to glycoprofile glycans
based on the degree of sialylation and the patterns of their
substituents. The ultrahigh resolution TOF MS confirmed the
presence of modified glycan structures, and putative glycan
monosaccharide compositions were determined by using the
high resolution and high mass accuracy of the TOF MS.
Although, the method has several advantages for the
glycosylation characterization of rHuEPO, in terms of the
simple instrumentation, small sample consumption, relatively
short analysis time and the feasibility of coupling CE with
different types of MS instruments, its major limitation is
probably the limited concentration sensitivity. However, in the
context of therapeutic glycoprotein characterization, highly
concentrated pharmaceuticals are commonly available. There-
fore, the presented CE-MS method can be regarded as an
orthogonal and complementary approach for glycoprofiling
protein pharmaceuticals.
In addition, PGC LC-MS/MS confirmed the presence of
sialylated glycan structures containing variable degrees of
acetylation. However, other glycan modifications were not
detected with PGC LC-MS/MS which indicates the potential
advantages of CE-MS over LC-MS for unraveling the structural
complexity of glycans released from glycoproteins.
Quality control of recombinant therapeutic proteins requires
determining the glycosylation profile and the occurrence of
secondary glycan modifications that may shed light on
additional biological properties that affect both pharmacody-
namics and pharmacokinetics. In combination with the high
quality of MS data, an improved insight into the glycan
heterogeneity of rHuEPO was possible. Our CE-MS analysis
can be considered as a promising alternative to assess the
glycosylation profile of therapeutic drugs and to evaluate the
quality of biosimilar products.
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